GlassScriptPhysician profile
Abby Yochim
NPI 1023368552
$8,062.50
in general payments reported to CMS, 2019-2025
44 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,225 · 2022: $1,503 · 2023: $3,678 · 2024: $1,513 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,235 · Travel and Lodging: $1,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,235.26 |
| Travel and Lodging | $1,099.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $2,023.06 | 2021-2024 | |
| Stryker Corporation | $1,225.50 | 2021-2024 | Cascadia Interbody System, Yukon Oct Spinal System, Spinemap |
| Nevro Corp. | $752.08 | 2021-2023 | Senza |
| Abbvie INC. | $354.13 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $268.86 | 2023-2024 | Hyqvia, Gammagard |
| Lilly USA, LLC | $264.83 | 2021-2024 | Amyvid, Emgality, Kisunla |
| Argenx US, INC. | $237.79 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Alexion Pharmaceuticals, INC. | $217.67 | 2021-2023 | Ultomiris, Soliris |
| Sk Life Science, INC. | $197.64 | 2022-2024 | |
| Mdd US Operations, LLC | $186.94 | 2021-2024 | Gocovri, Apokyn |
| Ucb, INC. | $177.90 | 2021-2024 | Briviact, Rystiggo, Zilbrysq |
| Acorda Therapeutics, INC | $171.55 | 2022-2024 | Inbrija |
| Merz Pharmaceuticals, LLC | $168.30 | 2021-2024 | Xeomin |
| Teva Pharmaceuticals USA, INC. | $165.42 | 2021-2024 | Austedo Xr |
| Amneal Pharmaceuticals LLC | $157.96 | 2022-2024 | Rytary, Ongentys 50mg Capsules 30 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $147.63 | 2021-2023 | Aimovig |
| Emd Serono, INC. | $134.73 | 2023-2024 | Mavenclad |
| Sumitomo Pharma America, INC. | $125.71 | 2023 | Aptiom |
| Eisai INC. | $96.18 | 2023-2024 | |
| Acadia Pharmaceuticals INC | $92.26 | 2021-2025 | Nuplazid |
| Averitas Pharma INC. | $90.38 | 2023-2024 | Qutenza |
| Grt US Holding, INC. | $65.65 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $59.91 | 2022 | |
| Csl Behring | $55.80 | 2022-2025 | Hizentra |
| Upsher-Smith Laboratories LLC | $55.49 | 2021-2023 | |
| Neurocrine Biosciences, INC. | $53.49 | 2023-2024 | Ingrezza, Ongentys |
| Sunovion Pharmaceuticals INC. | $52.24 | 2022 | |
| Celgene Corporation | $47.66 | 2023-2024 | Zeposia |
| Pfizer INC. | $45.15 | 2023 | |
| Ge Healthcare | $43.45 | 2024-2025 | |
| Avion Pharmaceuticals | $38.08 | 2022 | |
| Orthofix Medical, INC. | $37.36 | 2023 | Spinal-Stim, Spinal-Stim |
| Jazz Pharmaceuticals INC. | $35.17 | 2022-2023 | |
| Grifols USA, LLC | $28.53 | 2024 | Gamunex-C |
| Depuy Synthes Sales INC. | $26.42 | 2022 | |
| Medtronic, INC. | $22.28 | 2022 | |
| Genzyme Corporation | $19.61 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $19.46 | 2021 | |
| Incyte Corporation | $19.33 | 2025 | Monjuvi, Pemazyre |
| Collegium Pharmaceutical, INC. | $18.75 | 2023 | Belbuca |
| Biogen, INC. | $18.25 | 2023 | Skyclarys |
| Avanir Pharmaceuticals, INC. | $15.42 | 2021 | |
| Banner Life Sciences, LLC | $14.44 | 2022 | |
| Neurelis, INC. | $14.04 | 2024 | Valtoco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abby Yochim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.